| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Age-related lobular involution and risk of breast cancer.
|
J Natl Cancer Inst
|
2006
|
5.12
|
|
2
|
Selective estrogen-receptor modulators -- mechanisms of action and application to clinical practice.
|
N Engl J Med
|
2003
|
3.46
|
|
3
|
Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells.
|
Cancer Res
|
2009
|
3.30
|
|
4
|
The Role of Risk-Reducing Surgery in Hereditary Breast and Ovarian Cancer.
|
N Engl J Med
|
2016
|
2.72
|
|
5
|
In vivo quantitation of rare circulating tumor cells by multiphoton intravital flow cytometry.
|
Proc Natl Acad Sci U S A
|
2007
|
2.70
|
|
6
|
MR elastography of breast cancer: preliminary results.
|
AJR Am J Roentgenol
|
2002
|
2.65
|
|
7
|
Stratification of breast cancer risk in women with atypia: a Mayo cohort study.
|
J Clin Oncol
|
2007
|
2.58
|
|
8
|
Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer.
|
Cancer Res
|
2010
|
2.19
|
|
9
|
Intraperitoneal therapy of ovarian cancer using an engineered measles virus.
|
Cancer Res
|
2002
|
2.18
|
|
10
|
Satisfaction after contralateral prophylactic mastectomy: the significance of mastectomy type, reconstructive complications, and body appearance.
|
J Clin Oncol
|
2005
|
2.09
|
|
11
|
Assessment of the accuracy of the Gail model in women with atypical hyperplasia.
|
J Clin Oncol
|
2008
|
2.06
|
|
12
|
Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer.
|
Clin Cancer Res
|
2011
|
2.02
|
|
13
|
Folate receptor alpha as a tumor target in epithelial ovarian cancer.
|
Gynecol Oncol
|
2008
|
2.01
|
|
14
|
Current management strategies for ovarian cancer.
|
Mayo Clin Proc
|
2007
|
1.94
|
|
15
|
Analysis of gene expression in stage I serous tumors identifies critical pathways altered in ovarian cancer.
|
Gynecol Oncol
|
2009
|
1.82
|
|
16
|
High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases.
|
J Clin Oncol
|
2002
|
1.79
|
|
17
|
Recreational physical activity and risk of postmenopausal breast cancer based on hormone receptor status.
|
Arch Intern Med
|
2006
|
1.77
|
|
18
|
Association between mammographic density and age-related lobular involution of the breast.
|
J Clin Oncol
|
2010
|
1.70
|
|
19
|
ERBB2, TBX2, RPS6KB1, and MYC alterations in breast tissues of BRCA1 and BRCA2 mutation carriers.
|
Genes Chromosomes Cancer
|
2004
|
1.64
|
|
20
|
A pilot study of long-acting octreotide for symptomatic malignant ascites.
|
Oncology
|
2012
|
1.56
|
|
21
|
The use of a tropism-modified measles virus in folate receptor-targeted virotherapy of ovarian cancer.
|
Clin Cancer Res
|
2006
|
1.50
|
|
22
|
Proceedings of the international consensus conference on breast cancer risk, genetics, & risk management, April, 2007.
|
Breast J
|
2009
|
1.48
|
|
23
|
Surgical risk reduction: prophylactic salpingo-oophorectomy and prophylactic mastectomy.
|
Am J Obstet Gynecol
|
2004
|
1.47
|
|
24
|
p16(INK4a) expression and breast cancer risk in women with atypical hyperplasia.
|
Cancer Prev Res (Phila)
|
2011
|
1.45
|
|
25
|
APOBEC3B upregulation and genomic mutation patterns in serous ovarian carcinoma.
|
Cancer Res
|
2013
|
1.43
|
|
26
|
Serine protease HtrA1 modulates chemotherapy-induced cytotoxicity.
|
J Clin Invest
|
2006
|
1.37
|
|
27
|
Tumorgrafts as in vivo surrogates for women with ovarian cancer.
|
Clin Cancer Res
|
2014
|
1.35
|
|
28
|
Quantitation of circulating tumor cells in blood samples from ovarian and prostate cancer patients using tumor-specific fluorescent ligands.
|
Int J Cancer
|
2008
|
1.34
|
|
29
|
Mammary involution and breast cancer risk: transgenic models and clinical studies.
|
J Mammary Gland Biol Neoplasia
|
2009
|
1.32
|
|
30
|
Inherited determinants of ovarian cancer survival.
|
Clin Cancer Res
|
2010
|
1.32
|
|
31
|
Proceedings of the international consensus conference on breast cancer risk, genetics, & risk management, April, 2007.
|
Cancer
|
2008
|
1.28
|
|
32
|
Association of single nucleotide polymorphisms in glycosylation genes with risk of epithelial ovarian cancer.
|
Cancer Epidemiol Biomarkers Prev
|
2008
|
1.26
|
|
33
|
Risk of breast cancer and breast cancer characteristics in women treated with supradiaphragmatic radiation for Hodgkin lymphoma: Mayo Clinic experience.
|
Mayo Clin Proc
|
2003
|
1.26
|
|
34
|
Ki67: a time-varying biomarker of risk of breast cancer in atypical hyperplasia.
|
Breast Cancer Res Treat
|
2009
|
1.25
|
|
35
|
Estrogen bioactivation, genetic polymorphisms, and ovarian cancer.
|
Cancer Epidemiol Biomarkers Prev
|
2005
|
1.25
|
|
36
|
Epigenetic silencing of TCEAL7 (Bex4) in ovarian cancer.
|
Oncogene
|
2005
|
1.24
|
|
37
|
T-cell immunity to the folate receptor alpha is prevalent in women with breast or ovarian cancer.
|
J Clin Oncol
|
2006
|
1.24
|
|
38
|
Novel breast tissue feature strongly associated with risk of breast cancer.
|
J Clin Oncol
|
2009
|
1.23
|
|
39
|
Independent association of lobular involution and mammographic breast density with breast cancer risk.
|
J Natl Cancer Inst
|
2010
|
1.23
|
|
40
|
Association between cyclooxygenase-2 expression in atypical hyperplasia and risk of breast cancer.
|
J Natl Cancer Inst
|
2008
|
1.22
|
|
41
|
The ratios of CD8+ T cells to CD4+CD25+ FOXP3+ and FOXP3- T cells correlate with poor clinical outcome in human serous ovarian cancer.
|
PLoS One
|
2013
|
1.22
|
|
42
|
Contralateral prophylactic mastectomy is associated with a survival advantage in high-risk women with a personal history of breast cancer.
|
Ann Surg Oncol
|
2010
|
1.21
|
|
43
|
Evaluation of the Tyrer-Cuzick (International Breast Cancer Intervention Study) model for breast cancer risk prediction in women with atypical hyperplasia.
|
J Clin Oncol
|
2010
|
1.16
|
|
44
|
Assessment of hepatocyte growth factor in ovarian cancer mortality.
|
Cancer Epidemiol Biomarkers Prev
|
2011
|
1.14
|
|
45
|
Role of decreased levels of lipid phosphate phosphatase-1 in accumulation of lysophosphatidic acid in ovarian cancer.
|
Clin Cancer Res
|
2003
|
1.12
|
|
46
|
Lobular involution: localized phenomenon or field effect?
|
Breast Cancer Res Treat
|
2008
|
1.12
|
|
47
|
Breast biopsy utilization: a population-based study.
|
Arch Intern Med
|
2005
|
1.12
|
|
48
|
Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers.
|
Cancer
|
2003
|
1.11
|
|
49
|
Prophylactic mastectomy for BRCA1/2 carriers: progress and more questions.
|
J Clin Oncol
|
2004
|
1.10
|
|
50
|
Molecular pathogenesis and therapeutic targets in epithelial ovarian cancer.
|
J Cell Biochem
|
2007
|
1.09
|
|
51
|
Contralateral prophylactic mastectomy: long-term consistency of satisfaction and adverse effects and the significance of informed decision-making, quality of life, and personality traits.
|
Ann Surg Oncol
|
2011
|
1.07
|
|
52
|
Immunity and immune suppression in human ovarian cancer.
|
Immunotherapy
|
2011
|
1.07
|
|
53
|
An analysis of breast cancer risk in women with single, multiple, and atypical papilloma.
|
Am J Surg Pathol
|
2006
|
1.06
|
|
54
|
Tissue composition of mammographically dense and non-dense breast tissue.
|
Breast Cancer Res Treat
|
2011
|
1.05
|
|
55
|
Fracture risk in women with breast cancer: a population-based study.
|
J Bone Miner Res
|
2012
|
1.03
|
|
56
|
Breast cancer risk in women with radial scars in benign breast biopsies.
|
Breast Cancer Res Treat
|
2007
|
1.03
|
|
57
|
Relative weight at age 12 and risk of postmenopausal breast cancer.
|
Cancer Epidemiol Biomarkers Prev
|
2008
|
1.03
|
|
58
|
Polymorphisms in ABCB1 and ERCC2 associated with ovarian cancer outcome.
|
Int J Mol Epidemiol Genet
|
2011
|
1.00
|
|
59
|
Menstrual cycle and surgical treatment of breast cancer: findings from the NCCTG N9431 study.
|
J Clin Oncol
|
2009
|
0.99
|
|
60
|
Elevated fibroblast growth factor 23 in women with malignant ovarian tumors.
|
Mayo Clin Proc
|
2005
|
0.99
|
|
61
|
Sclerosing adenosis and risk of breast cancer.
|
Breast Cancer Res Treat
|
2014
|
0.99
|
|
62
|
Pseudoangiomatous stromal hyperplasia and breast cancer risk.
|
Ann Surg Oncol
|
2010
|
0.98
|
|
63
|
Epigenome-wide ovarian cancer analysis identifies a methylation profile differentiating clear-cell histology with epigenetic silencing of the HERG K+ channel.
|
Hum Mol Genet
|
2013
|
0.97
|
|
64
|
Reoperations after prophylactic mastectomy with or without implant reconstruction.
|
Cancer
|
2003
|
0.96
|
|
65
|
Functional folate receptor alpha is elevated in the blood of ovarian cancer patients.
|
PLoS One
|
2009
|
0.96
|
|
66
|
Histologic findings in normal breast tissues: comparison to reduction mammaplasty and benign breast disease tissues.
|
Breast Cancer Res Treat
|
2011
|
0.94
|
|
67
|
Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma.
|
Gynecol Oncol
|
2011
|
0.93
|
|
68
|
Polymorphisms in NF-kappaB inhibitors and risk of epithelial ovarian cancer.
|
BMC Cancer
|
2009
|
0.93
|
|
69
|
Inherited variants in regulatory T cell genes and outcome of ovarian cancer.
|
PLoS One
|
2013
|
0.93
|
|
70
|
Minichromosome maintenance protein 7 as a potential prognostic factor for progression-free survival in high-grade serous carcinomas of the ovary.
|
Mod Pathol
|
2010
|
0.92
|
|
71
|
Risk of ovarian cancer and inherited variants in relapse-associated genes.
|
PLoS One
|
2010
|
0.90
|
|
72
|
Immunomagnetic diffractometry for detection of diagnostic serum markers.
|
J Am Chem Soc
|
2007
|
0.90
|
|
73
|
Benign breast disease and the risk of subsequent breast cancer in African American women.
|
Cancer Prev Res (Phila)
|
2012
|
0.89
|
|
74
|
Microsatellite instability in hereditary and sporadic breast cancers.
|
Int J Cancer
|
2003
|
0.88
|
|
75
|
Estrogen receptor expression in atypical hyperplasia: lack of association with breast cancer.
|
Cancer Prev Res (Phila)
|
2011
|
0.88
|
|
76
|
Impact of reconstruction and reoperation on long-term patient-reported satisfaction after contralateral prophylactic mastectomy.
|
Ann Surg Oncol
|
2014
|
0.88
|
|
77
|
Variation at 8q24 and 9p24 and risk of epithelial ovarian cancer.
|
Twin Res Hum Genet
|
2010
|
0.87
|
|
78
|
Bilateral oophorectomy and breast cancer risk reduction among women with a family history.
|
Cancer Detect Prev
|
2004
|
0.85
|
|
79
|
Gene set analysis of survival following ovarian cancer implicates macrolide binding and intracellular signaling genes.
|
Cancer Epidemiol Biomarkers Prev
|
2012
|
0.85
|
|
80
|
An HLA-DR-degenerate epitope pool detects insulin-like growth factor binding protein 2-specific immunity in patients with cancer.
|
Cancer Res
|
2008
|
0.85
|
|
81
|
Flat epithelial atypia and risk of breast cancer: A Mayo cohort study.
|
Cancer
|
2015
|
0.84
|
|
82
|
Prophylactic and therapeutic mastectomy in BRCA mutation carriers: can the nipple be preserved?
|
Ann Surg Oncol
|
2011
|
0.84
|
|
83
|
Pathophysiology and palliation of inoperable bowel obstruction in patients with ovarian cancer.
|
J Support Oncol
|
2004
|
0.84
|
|
84
|
Nutritional status, CT body composition measures and survival in ovarian cancer.
|
Gynecol Oncol
|
2013
|
0.84
|
|
85
|
Polymorphisms in TCEAL7 and risk of epithelial ovarian cancer.
|
Gynecol Oncol
|
2009
|
0.84
|
|
86
|
A degenerate HLA-DR epitope pool of HER-2/neu reveals a novel in vivo immunodominant epitope, HER-2/neu88-102.
|
Clin Cancer Res
|
2010
|
0.82
|
|
87
|
Large-scale evaluation of common variation in regulatory T cell-related genes and ovarian cancer outcome.
|
Cancer Immunol Res
|
2014
|
0.82
|
|
88
|
Independent test set performance in the prediction of early relapse in ovarian cancer with gene expression profiles.
|
Clin Cancer Res
|
2005
|
0.82
|
|
89
|
Targeting and palliating malignant ascites: an overview of an upcoming clinical trial from the north central cancer treatment group.
|
Support Cancer Ther
|
2005
|
0.81
|
|
90
|
Benign breast disease: emerging findings in a diverse population.
|
Breast J
|
2007
|
0.79
|
|
91
|
Multimodal therapy including neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) for stage IIB to IV cervical cancer.
|
Am J Obstet Gynecol
|
2002
|
0.78
|
|
92
|
Long-term follow-up of women with ovarian cancer after positive second-look laparotomy.
|
Gynecol Oncol
|
2003
|
0.78
|
|
93
|
Are cancer survivors/patients knowledgeable about osteoporosis? Results from a survey of 285 chemotherapy-treated cancer patients and their companions.
|
J Nutr Educ Behav
|
2008
|
0.78
|
|
94
|
Heterogeneous role of caspase-8 in fenretinide-induced apoptosis in epithelial ovarian carcinoma cell lines.
|
Mol Pharmacol
|
2003
|
0.78
|
|
95
|
Her-2/neu expression in ovarian cancer: pre- and postexposure to platinum chemotherapy.
|
Gynecol Oncol
|
2003
|
0.77
|
|
96
|
Long-term survival of patients with advanced/recurrent carcinoma of cervix and vagina after neoadjuvant treatment with methotrexate, vinblastine, doxorubicin, and cisplatin with or without the addition of molgramostim, and review of the literature.
|
Am J Clin Oncol
|
2002
|
0.77
|
|
97
|
Ki-67 expression in sclerosing adenosis and adjacent normal breast terminal ductal lobular units: a nested case-control study from the Mayo Benign Breast Disease Cohort.
|
Breast Cancer Res Treat
|
2015
|
0.77
|
|
98
|
Identification of a broad coverage HLA-DR degenerate epitope pool derived from carcinoembryonic antigen.
|
Cancer Immunol Immunother
|
2009
|
0.77
|
|
99
|
Atypical hyperplasia of the breast.
|
N Engl J Med
|
2015
|
0.77
|
|
100
|
Breast cancer after prophylactic mastectomy (bilateral or contralateral prophylactic mastectomy), a clinical entity: presentation, management, and outcomes.
|
Breast Cancer Res Treat
|
2015
|
0.76
|
|
101
|
Opsoclonus as a suspected paraneoplastic syndrome of endometrial cancer.
|
Rare Tumors
|
2010
|
0.75
|
|
102
|
Gene signature model for breast cancer risk prediction for women with sclerosing adenosis.
|
Breast Cancer Res Treat
|
2015
|
0.75
|
|
103
|
Complex fibroadenoma and breast cancer risk: a Mayo Clinic Benign Breast Disease Cohort Study.
|
Breast Cancer Res Treat
|
2015
|
0.75
|
|
104
|
Lobular neoplasia: how to manage with partial understanding.
|
Oncology (Williston Park)
|
2011
|
0.75
|
|
105
|
Ovarian cancer care: it's time for "personalized" approaches.
|
Oncology (Williston Park)
|
2010
|
0.75
|
|
106
|
Risk-Reducing Surgery in Hereditary Breast and Ovarian Cancer.
|
N Engl J Med
|
2016
|
0.75
|
|
107
|
Helping people cope with bereavement: an opportunity for health care providers to link Web-based resources across Minnesota.
|
Minn Med
|
2006
|
0.75
|
|
108
|
Current status of prophylactic mastectomy.
|
Oncology (Williston Park)
|
2002
|
0.75
|
|
109
|
Stories of breast cancer through art.
|
Oncol Nurs Forum
|
2003
|
0.75
|
|
110
|
A piece of my mind. The octogenarian's plan.
|
JAMA
|
2005
|
0.75
|